AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2026 Quarter 4; ICD-10-PCS New/Revised Codes Section X – New Technology
Introduction of New Therapeutic Substances
In table XW0, Introduction of Anatomical Regions, six new substance values were added for the substances listed below. These substances have the qualifier value New Technology Group 12. Device/Substance/Technology 4 Elamipretide 5 Ifezuntirgene Inilparvovec 6 Landiolol Antiarrhythmic 7 Zimislecel Allogeneic Stem Cell-derived Islet Cell Therapy Elamipretide Elamipretide is administered subcutaneously to improve muscle strength in adults and patients with Barth syndrome. Barth syndrome is characterized by mucocutaneous blistering, nail deformities, and the absence of skin on the legs and feet. Elamipretide targets mitochondrial dysfunction to regulate cellular damage, inflammation, and disease progression. Ifezuntirgene Inilparvovec Ifezuntirgene Inilparvovec is an experimental...
Subscribe or sign in to view the full article.
Article Overview
The article describes an update to an ICD-10-PCS table and summarizes four therapeutic substances, including their general areas of use, delivery approaches, and associated conditions. It is relevant to readers following new therapeutic technologies and related medical coding updates.
Why This Topic Matters
New therapeutic substances can be relevant to coding and clinical documentation as the technologies enter use. This overview connects a table update with general background on the therapies and the clinical areas they address.
Article Sections
-
New substance values
Introduces the addition of new substance values in an ICD-10-PCS table and identifies their new technology grouping.
-
Elamipretide
Summarizes the therapy’s general clinical context, including its connection to Barth syndrome.
-
Ifezuntirgene Inilparvovec
Provides background on an investigational gene therapy and its neurological treatment context.
-
Landiolol Antiarrhythmic
Describes the therapy’s general cardiovascular context and method of administration.
-
Zimislecel
Summarizes an investigational cell therapy and its connection to type 1 diabetes.
What You Will Learn
- Which therapeutic substances are covered in the table update
- The general clinical areas associated with each therapy
- The administration and treatment contexts discussed in the article
- intended_audiences ג
Who Should Read This
- Medical coders
- Clinical documentation professionals
- Healthcare professionals tracking therapeutic technologies
- Medical coding researchers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com